相似文献
1
Translational nanoparticle engineering for cancer vaccines.
Oncoimmunology. 2017 Feb 22;6(10):e1290036. doi: 10.1080/2162402X.2017.1290036. eCollection 2017.
2
Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy.
Adv Healthc Mater. 2021 Mar;10(5):e2000845. doi: 10.1002/adhm.202000845. Epub 2020 Aug 12.
3
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23.
4
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
J Virol. 2017 Jan 31;91(4). doi: 10.1128/JVI.01844-16. Print 2017 Feb 15.
5
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Haematologica. 2002 Sep;87(9):989-1001.
6
Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
J Exp Clin Cancer Res. 2016 Oct 26;35(1):168. doi: 10.1186/s13046-016-0444-6.
7
Multifunctional nanoparticles for cancer immunotherapy.
Hum Vaccin Immunother. 2016 Jul 2;12(7):1863-75. doi: 10.1080/21645515.2016.1147635. Epub 2016 Feb 22.
8
In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Jan;11(1):e1524. doi: 10.1002/wnan.1524. Epub 2018 Apr 18.
9
Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses.
J Allergy Clin Immunol. 2018 Nov;142(5):1558-1570. doi: 10.1016/j.jaci.2017.08.049. Epub 2018 Jan 31.
10
Nanotechnology as a therapeutic tool to combat microbial resistance.
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1803-15. doi: 10.1016/j.addr.2013.07.011. Epub 2013 Jul 24.
引用本文的文献
1
Nanotechnology for immuno-oncology.
Nat Cancer. 2025 Aug 7. doi: 10.1038/s43018-025-01025-x.
2
CEA-Functionalized Gold Nanoparticles as a Nanovaccine Platform: In Vitro Evaluation of Cytocompatibility, Cellular Uptake, and Antigen Processing.
Vaccines (Basel). 2025 Jun 21;13(7):668. doi: 10.3390/vaccines13070668.
3
Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.
Front Immunol. 2024 Nov 29;15:1453753. doi: 10.3389/fimmu.2024.1453753. eCollection 2024.
4
Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.
Pharmaceutics. 2024 Sep 18;16(9):1218. doi: 10.3390/pharmaceutics16091218.
5
Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.
Pharmaceutics. 2024 Aug 16;16(8):1076. doi: 10.3390/pharmaceutics16081076.
6
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.
Biomolecules. 2024 Apr 21;14(4):503. doi: 10.3390/biom14040503.
7
Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis.
Hum Vaccin Immunother. 2023 Aug;19(2):2254262. doi: 10.1080/21645515.2023.2254262. Epub 2023 Sep 20.
8
Peptide-based vaccine for cancer therapies.
Front Immunol. 2023 Aug 16;14:1210044. doi: 10.3389/fimmu.2023.1210044. eCollection 2023.
9
Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment.
Front Pharmacol. 2023 May 3;14:1174330. doi: 10.3389/fphar.2023.1174330. eCollection 2023.
10
Aerosol pulmonary immune engineering.
Adv Drug Deliv Rev. 2023 Aug;199:114831. doi: 10.1016/j.addr.2023.114831. Epub 2023 Apr 24.
本文引用的文献
1
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Nature. 2016 Jun 16;534(7607):396-401. doi: 10.1038/nature18300. Epub 2016 Jun 1.
2
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2016 Jun;17(6):822-835. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27.
3
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Breast Cancer Res Treat. 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18.
4
Cancer statistics, 2016.
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
5
Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells.
Nanomedicine. 2016 Apr;12(3):677-687. doi: 10.1016/j.nano.2015.11.002. Epub 2015 Dec 1.
6
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.
Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18.
7
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
J Biol Chem. 2016 Jan 15;291(3):1123-36. doi: 10.1074/jbc.M115.683011. Epub 2015 Nov 10.
8
Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs.
Nano Lett. 2015 Nov 11;15(11):7300-6. doi: 10.1021/acs.nanolett.5b02497. Epub 2015 Oct 20.
9
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
Oncoimmunology. 2015 May 7;4(8):e1026529. doi: 10.1080/2162402X.2015.1026529. eCollection 2015 Aug.
10
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2015 Oct;10(10):1458-67. doi: 10.1097/JTO.0000000000000653.
Zotero 插件